Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Deals

Youwe Bio’s Series B Financing to Advance Microneedle Technology Commercialization

Fineline Cube Jun 30, 2022

China-based Youwe (Zhuhai) Biotechnology Co., Ltd, a developer of soluble microneedle transdermal drug delivery technology,...

Policy / Regulatory

NHSA Updates NRDL with Focus on Expert Review and Simplified Renewals

Fineline Cube Jun 30, 2022

The National Healthcare Security Administration (NHSA) has released the “2022 National Reimbursement Drug List (NRDL)...

Company Drug

Ascletis Pharma Doses First Patient in China’s Phase II Trial for HIV-1 Treatment with ASC22

Fineline Cube Jun 29, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced the dosing of the first patient in its...

Company Drug

Jixing Pharmaceuticals’ Aficamten Receives CDE Approval for Phase III HCM Study

Fineline Cube Jun 29, 2022

China-based Ji Xing Pharmaceuticals announced receiving approval from the Center for Drug Evaluation (CDE) to...

Company Drug

BDgene Advances CRISPR-Based BD111 for Herpes Keratitis with IND Filing

Fineline Cube Jun 29, 2022

Shanghai BDgene Technology Co., Ltd has completed efficacy and preliminary safety studies for BD111, its...

Company Deals

MicroPort NeuroTech Lists in Hong Kong with $43.3 Million IPO

Fineline Cube Jun 29, 2022

MicroPort NeuroTech Limited has successfully completed its initial public offering (IPO) on the Hong Kong...

Company Drug

Bayer’s Kerendia Approved by China’s NMPA for Diabetic Kidney Disease

Fineline Cube Jun 29, 2022

The National Medical Products Administration (NMPA) has approved Bayer’s (ETR: BAYN) Category 1 drug Kerendia...

Company Drug

Hengrui Medicine’s SHR3680 Approved for High Burden Metastatic Prostate Cancer

Fineline Cube Jun 29, 2022

China’s Hengrui Medicine Co., Ltd. (SHA: 600276) announced that its Category 1 drug SHR3680 has...

Company Deals R&D

Legend Biotech Collaborates with Trinity College Dublin on CAR-T Therapies for Solid Tumors

Fineline Cube Jun 29, 2022

China-based Legend Biotech Corporation (NASDAQ: LEGN) has formed a partnership with Trinity College Dublin and...

Company Deals

AnchorDx and West China Hospital Collaborate on Lung Cancer Early Diagnosis

Fineline Cube Jun 29, 2022

Guangzhou-based AnchorDx and West China Hospital of Sichuan University have entered into a transfer agreement...

Company Drug

Akeso Biopharma’s Cadonilimab Approved for Cervical Cancer Treatment

Fineline Cube Jun 29, 2022

China-based biotech company Akeso Biopharma (HKG: 9926) announced that its self-discovered bispecific antibody (BsAb) cadonilimab...

Company Drug

Humanwell Healthcare Wins NMPA Approval for RFUS-144 in Pain Management

Fineline Cube Jun 29, 2022

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced receiving approval from the National Medical...

Company Deals

LaNova Medicines Secures Series B Funding to Advance Oncology Pipeline

Fineline Cube Jun 29, 2022

China-based LaNova Medicines has successfully closed a Series B financing round, raising an undisclosed sum...

Company Deals

GenFleet Collaborates with BioLineRx to Develop Motixafortide for Pancreatic Cancer in China

Fineline Cube Jun 29, 2022

China-based GenFleet Therapeutics has entered into a collaboration with Israel’s BioLineRx Ltd (NASDAQ: BLRX) to...

Company Deals

Henlius and Palleon Partner on HER2-Targeted Antibody-Sialidase Fusion Protein

Fineline Cube Jun 29, 2022

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic partnership with US-based Palleon Pharmaceuticals...

Company R&D

Lundbeck Initiates TALISMAN Study on Multiple System Atrophy in China and EU

Fineline Cube Jun 28, 2022

Danish-based Lundbeck (OTCMKTS: HLUBF) has announced plans to initiate a global investigational study on multiple...

Company Deals

OCON Healthcare Partners with Bio Genuine for China Marketing Rights and Women’s Health Product Development

Fineline Cube Jun 28, 2022

Israel-based OCON Healthcare, a specialist in uterine drug delivery, has entered into a license agreement...

Company Deals

Expeclinlab Raises RMB 185 Million to Boost Clinical Mass Spectrometry Business

Fineline Cube Jun 28, 2022

Focused Photonics Inc’s (SHE: 300203) subsidiary Expeclinlab has secured RMB 185 million (USD 27.7 million)...

Company Deals

Beijing Luzhu Biotechnology Secures Series C Funding for Meningococcal Vaccine Development

Fineline Cube Jun 28, 2022

China-based Beijing Luzhu Biotechnology Co., Ltd has reportedly secured an undisclosed amount in a Series...

Company Drug

Eli Lilly’s Donanemab Receives Tacit Approval for Alzheimer’s Clinical Trial in China

Fineline Cube Jun 28, 2022

The Center for Drug Evaluation (CDE) website indicates that US major Eli Lilly’s (NYSE: LLY)...

Posts pagination

1 … 708 709 710 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.